Susan Stewart
General Counsel chez CANDEL THERAPEUTICS, INC.
Fortune : 55 752 $ au 31/03/2024
Profil
Susan B.
Stewart is currently the Director at Regulatory Affairs Professionals Society, Chief Regulatory Officer at Candel Therapeutics, Inc., and Chief Regulatory Officer at Rezolute, Inc. She previously worked as the Director, VP-Quality & Regulatory Affairs at MG Biotherapeutics LLC, Quality Assurance Manager at Abbott Laboratories, Principal at Diacrin, Inc. (Delaware), Vice President-Regulatory Affairs at Genzyme Corp., Vice President-Regulatory Affairs at TransMolecular, Inc., SVP-Regulatory Affairs, Quality & Compliance at Tokai Pharmaceuticals, Inc., Chief Regulatory Officer at Kaleido Biosciences, Inc., Chief Regulatory Officer at Frequency Therapeutics, Inc., and Head-Regulatory Affairs at resTORbio, Inc. Ms. Stewart received her undergraduate degree from the University of Massachusetts and her graduate degrees from Concord Law School and Maurice A.
Deane School of Law at Hofstra University.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
HARBORONE BANCORP INC
0,01% | 28/03/2024 | 5 230 ( 0,01% ) | 55 752 $ | 31/03/2024 |
Postes actifs de Susan Stewart
| Sociétés | Poste | Début |
|---|---|---|
| CANDEL THERAPEUTICS, INC. | General Counsel | 01/10/2020 |
| REZOLUTE, INC. | General Counsel | 01/01/2022 |
Regulatory Affairs Professionals Society
 Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Director/Board Member | - |
Anciens postes connus de Susan Stewart
| Sociétés | Poste | Fin |
|---|---|---|
| KORRO BIO, INC. | General Counsel | 30/04/2023 |
| KALEIDO BIOSCIENCES, INC. | General Counsel | 01/04/2022 |
Tokai Pharmaceuticals, Inc.
 Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Compliance Officer | 01/01/2015 |
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | General Counsel | 01/01/2005 |
| MG Biotherapeutics LLC | Director/Board Member | 01/01/2005 |
Formation de Susan Stewart
| University of Massachusetts | Undergraduate Degree |
| Concord Law School | Graduate Degree |
| Maurice A. Deane School of Law at Hofstra University | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 4 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| CANDEL THERAPEUTICS, INC. | Health Technology |
| REZOLUTE, INC. | Health Technology |
| KALEIDO BIOSCIENCES, INC. | Health Technology |
| Entreprise privées | 8 |
|---|---|
Diacrin, Inc. (Delaware)
 Diacrin, Inc. (Delaware) Medical SpecialtiesHealth Technology Diacrin, Inc. develops human cell transplant therapeutic products. The company is headquartered in Wilmington, DE. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Regulatory Affairs Professionals Society
Regulatory Affairs Professionals Society Miscellaneous Commercial ServicesCommercial Services Regulatory Affairs Professionals Society is a non-profit organization that offers healthcare products. The non-profit company is based in Rockville, MD. | Commercial Services |
TransMolecular, Inc.
 TransMolecular, Inc. BiotechnologyHealth Technology TransMolecular is an oncology-focused biotechnology company committed to developing novel proprietary drugs to diagnose and treat human diseases using a novel tumor targeting platform called TM601. Their development program to date has explored the therapeutic use of TM601 in cancer and neovascular diseases of the eye, and their lead candidate, TM601 conjugated to the radioactive isotope 131I, has a Special Protocol Agreement (SPA) with the FDA for a pivotal, Phase 3 trial in newly diagnosed glioblastoma multiforme (glioma). TM601 has unique properties of highly specific tumor cell binding and internalization while not affecting normal cells, targeting both primary disease sites and metastases. The interaction of TM601 with a specific protein known to be over-expressed on the surface of tumor cells and vascular endothelium is implicated in these tumor-specific binding properties. Conjugated to an anti-cancer radioactive isotope, TM601 has been successful in human and animal models in demonstrating selective targeting and uptake in a number of different tumor types, and in tumor locations within the central nervous system (CNS) and peripherally. Expanded research confirms that TM601 can deliver a variety of conjugates, creating potential for development of a wide array of anti-cancer therapies. In addition to the tumor targeting capability of TM601, a number of studies have also revealed that TM0601 exerts robust anti-angiogenic effects on vessels associated with neovascular disease. Pursuing this anti-angiogenic potential further, They have also determined the utility of TM601 in animal ophthalmic models. The company is leveraging its platform in strategic collaborations with partners seeking to expand product pipelines, extend product life-cycles for existing anti-tumor compounds, or optimize therapeutic activity of marginally effective or restrictively toxic drugs. | Health Technology |
| MG Biotherapeutics LLC | |
Tokai Pharmaceuticals, Inc.
Tokai Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Tokai Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in developing novel proprietary therapies for the treatment of prostate cancer and hormonally driven diseases. The company was founded by Joseph A. Yanchik, Gregory L. Verdine, and Seth L. Harrison on March 26, 2004 and is headquartered in Boston, MA. | Health Technology |
Frequency Therapeutics, Inc.
 Frequency Therapeutics, Inc. BiotechnologyHealth Technology Frequency Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the business of developing therapeutics to activate a person's innate regenerative potential to restore function. The firm is also involved in creating and commercializing therapeutics to potentially transform the lives of individuals by repairing or reversing damage done to cells, tissue, and organs. The company was founded by Robert S. Langer, David L. Lucchino, Christopher R. Loosey, and Will J. McLean on November 13, 2014 and is headquartered in Lexington, MA. | Health Technology |
resTORbio, Inc.
 resTORbio, Inc. BiotechnologyHealth Technology resTORbio, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the development and commercialization of medicines for aging-related diseases and conditions. It offers an immunotherapy under the TORC1 program. The company was founded by Chen Schor and Joan Mannick on July 5, 2016 and is headquartered in Boston, MA. | Health Technology |
